Days After India Announced ?Precautionary Dose? for Health Care, Frontline Workers and Population Over 60 with Comorbidities, Center Government Reported to Be Discussing with Gennova Biopharmaceuticals based in Pune to consider its mRNA vaccine for the booster dose, a report said. Gennova?s messenger RNA or mRNA vaccine is in an advanced trial phase, where it has already completed phase 2 studies and progressed well into phase 3. In addition, the Reading Center issues guidelines for the booster dose, vaccination of children between the ages of 15 and 18